Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis

被引:38
作者
Suzuki, Minoru
Sakurai, Yoshinori
Masunaga, Shinichiro
Kinashi, Yuko
Nagata, Kenji
Maruhashi, Akira
Ono, Koji
机构
[1] Kyoto Univ, Res Reactor Inst, Particle Oncol Res Ctr, Osaka 5900494, Japan
[2] Kyoto Univ, Res Reactor Inst, Dept Radiat Life Sci, Div Med Phys, Osaka, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 05期
关键词
boron neutron capture therapy; malignant pleural mesothelioma; RADIATION-THERAPY; MANAGEMENT; LUNG; IRRADIATION; CANCER; TUMORS; BRAIN;
D O I
10.1016/j.ijrobp.2006.08.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma (MPM) from a viewpoint of dose distribution analysis using Simulation Environment for Radiotherapy Applications (SERA), a currently available BNCT treatment planning system. Methods and Materials: The BNCT treatment plans were constructed for 3 patients with MPM using the SERA system, with 2 opposed anterior-posterior beams. The B-10 concentrations in the tumor and normal lung in this study were assumed to be 84 and 24 ppm, respectively, and were derived from data observed in clinical trials. The maximum, mean, and minimum doses to the tumors and the normal lung were assessed for each plan. The doses delivered to 5% and 95% of the tumor volume, D-05 and D-95, were adopted as the representative dose for the maximum and minimum dose, respectively. Results: When the D-05 to the normal ipsilateral lung was 5 Gy-Eq, the D-95 and mean doses delivered to the normal lung were 2.2-3.6 and 3.5-4.2 Gy-Eq, respectively. The mean doses delivered to the tumors were 22.4-27.2 Gy-Eq. The D-05 and D-95 doses to the tumors were 9.6-15.0 and 31.5-39.5 Gy-Eq, respectively. Conclusions: From a viewpoint of the dose-distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses. (c) 2006 Elsevier Inc.
引用
收藏
页码:1584 / 1589
页数:6
相关论文
共 50 条
  • [31] FIRST EVALUATION OF THE BIOLOGIC EFFECTIVENESS FACTORS OF BORON NEUTRON CAPTURE THERAPY (BNCT) IN A HUMAN COLON CARCINOMA CELL LINE
    Alejandra Dagrosa, Maria
    Crivello, Martin
    Perona, Marina
    Thorp, Silvia
    Alberto Santa Cruz, Gustavo
    Pozzi, Emiliano
    Casal, Mariana
    Thomasz, Lisa
    Cabrini, Romulo
    Kahl, Steven
    Juan Juvenal, Guillermo
    Alberto Pisarev, Mario
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (01): : 262 - 268
  • [32] Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer
    Trivillin, Veronica A.
    Pozzi, Emiliano C. C.
    Colombo, Lucas L.
    Thorp, Silvia I.
    Garabalino, Marcela A.
    Monti Hughes, Andrea
    Gonzalez, Sara J.
    Farias, Ruben O.
    Curotto, Paula
    Santa Cruz, Gustavo A.
    Carando, Daniel G.
    Schwint, Amanda E.
    [J]. RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2017, 56 (04) : 365 - 375
  • [33] Arene ruthenium dithiolato-carborane complexes for boron neutron capture therapy (BNCT)
    Romero-Canelon, Isolda
    Phoenix, Ben
    Pitto-Barry, Anais
    Johanna Tran
    Soldevila-Barreda, Joan J.
    Kirby, Nigel
    Green, Stuart
    Sadler, Peter J.
    Barry, Nicolas P. E.
    [J]. JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2015, 796 : 17 - 25
  • [34] A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT)
    Lamba, Manisha
    Goswami, Avijit
    Bandyopadhyay, Anupam
    [J]. CHEMICAL COMMUNICATIONS, 2021, 57 (07) : 827 - 839
  • [35] Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model
    Emiliano C. C. Pozzi
    Jorge E. Cardoso
    Lucas L. Colombo
    Silvia Thorp
    Andrea Monti Hughes
    Ana J. Molinari
    Marcela A. Garabalino
    Elisa M. Heber
    Marcelo Miller
    Maria E. Itoiz
    Romina F. Aromando
    David W. Nigg
    Jorge Quintana
    Verónica A. Trivillin
    Amanda E. Schwint
    [J]. Radiation and Environmental Biophysics, 2012, 51 : 331 - 339
  • [36] BORON NEUTRON-CAPTURE THERAPY IN MALIGNANT-MELANOMA
    CHARTIER, C
    KOESSLER, A
    ABBE, JC
    SAHEL, J
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1993, 120 (09): : 631 - 634
  • [37] Comparison between proton boron fusion therapy (PBFT) and boron neutron capture therapy (BNCT): a monte carlo study
    Jung, Joo-Young
    Yoon, Do-Kun
    Barraclough, Brendan
    Lee, Heui Chang
    Suh, Tae Suk
    Lu, Bo
    [J]. ONCOTARGET, 2017, 8 (24) : 39774 - 39781
  • [38] Boron neutron capture therapy for malignant tumors related to meningiomas
    Miyatake, Shin-Ichi
    Tamura, Yoji
    Kawabata, Shinji
    Iida, Kyoko
    Kuroiwa, Toshihiko
    Ono, Koji
    [J]. NEUROSURGERY, 2007, 61 (01) : 82 - 90
  • [39] Perceptions of Canadian Radiation Oncologists, Medical Physicists, and Radiation Trainees about the Feasibility and Need of Boron Neutron Capture Therapy (BNCT) in Canada: A National Survey
    Al-Bader, Al-Retage
    Agapito, John
    Pan, Ming
    [J]. CANCERS, 2023, 15 (14)
  • [40] Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era
    Minoru Suzuki
    [J]. International Journal of Clinical Oncology, 2020, 25 : 43 - 50